title: Optimum dosing of ipilimumab in melanoma: too little, too late?
authors.affiliation: Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia. Electronic address: alexander.menzies@sydney.edu.au.
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Menzies
authors.affiliation: Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
mesh_terms: D000911:Antibodies, Monoclonal; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma; D012878:Skin Neoplasms
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab